SCHEMBL3824880

SCHEMBL3824880

Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1Nc1ncccc1-c1cc(NC2CC2)ncn1

nearest known ligand 0.74

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.74
TEK Q02763 4/20 0.74
BRAF P15056 10/20 0.65
LCK P06239 3/20 0.65
MAPK14 Q16539 1/20 0.65
INSR P06213 2/20 0.61
LYN P07948 2/20 0.61
SRC P12931 2/20 0.61
HCK P08631 1/20 0.61
BTK Q06187 1/20 0.54
CSF1R P07333 1/20 0.53
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51
APEX1 P27695 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3826272 0.94 KDR (0.74) KDRTEKBRAFLCKMAPK14
SCHEMBL3823481 0.90 KDR (0.64) KDRTEKBRAFLCKMAPK14
SCHEMBL3589391 0.88 KDR (0.59) KDRTEKBRAFLCKMAPK14
SCHEMBL3823189 0.87 BRAF (0.64) KDRTEKBRAFLCKMAPK14
SCHEMBL3823531 0.87 KDR (0.79) KDRTEKBRAFLCKMAPK14
SCHEMBL3830996 0.86 BRAF (0.59) KDRTEKBRAFLCKMAPK14
SCHEMBL3824106 0.86 KDR (0.60) KDRTEKBRAFLCKMAPK14
SCHEMBL3823435 0.86 KDM4E (0.56) KDRTEKBRAFLCKMAPK14
SCHEMBL3823342 0.85 LCK (0.65) KDRTEKBRAFLCKMAPK14
SCHEMBL1264834 0.85 KDR (1.00) KDRTEKBRAFLCKMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101421262-A Compounds and compositions as protein kinase inhibitors IRM LLC (VG) 2009-04-29 CN claimed
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-03-12 US claimed
EP-1981870-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-10-22 EP claimed
WO-2007092531-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-08-16 WO claimed
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-03-12 US disclosed
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-03-12 US disclosed
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-03-12 US disclosed
WO-2007092531-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069327-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS SRC, BMX, FYN KDR 95/4885TEK 375/4885BRAF 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.